Balyasny Asset Management
IMNM icon

Balyasny Asset Management’s Immunome IMNM Stock Holding History

Balyasny Asset Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-251,396
Closed -$5.5M – 3237
2026
Q1 		$5.5M Sell
251,396
-1,178,284
-82% -$26.2M 0.01% 1331
2025
Q4 		$30.7M Buy
+1,429,680
New +$25.1M 0.04% 524
2025
Q3 		– Sell
-109,754
Closed -$1.02M – 3168
2025
Q2 		$1.02M Buy
+109,754
New +$900K ﹤0.01% 2030
2024
Q3 		– Sell
-375,242
Closed -$4.54M – 2931
2024
Q2 		$4.54M Buy
375,242
+220,754
+143% +$3.45M 0.01% 1216
2024
Q1 		$3.81M Buy
154,488
+125,839
+439% +$2.55M 0.01% 1323
2023
Q4 		$307K Buy
+28,649
New +$238K ﹤0.01% 2151

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Balyasny Asset Management's IMNM Position: Q2 2026 in Review

Balyasny Asset Management sold out of Immunome (IMNM) in Q2 2026, closing a stake of 251,396 shares — an estimated $5.5M sold.

Balyasny Asset Management first reported a position in IMNM in Q4 2023 and held it in 6 quarters. The position peaked at $30.7M in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Balyasny Asset Management reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 251,396 Immunome shares in Q2 2026, an estimated $5.5M.
  • Balyasny Asset Management first reported a position in Immunome in Q4 2023 and held it in 6 quarters.
  • Balyasny Asset Management's Immunome position peaked at $30.7M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.